Publications by authors named "Kyu-Young Lee"
Article Synopsis
- A study focused on identifying genetic variants linked to schizophrenia specifically in the Korean population, as previous large-scale studies mainly involved individuals of European ancestry.
- Researchers recruited 1,670 schizophrenia patients and 2,271 healthy controls, testing over 6.6 million SNPs, and discovered a significant new variant (rs2423464) associated with the condition.
- The polygenic risk scores (PRS) derived from a combination of East Asian and European GWASs were more effective in explaining the genetic variance in schizophrenia among Koreans than those from single-ancestry studies.
Efficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial.
Psychiatry Investig
July 2024
Objective: This study was performed to evaluate the efficacy and safety of lurasidone (160 mg/day) compared to quetiapine XR (QXR; 600 mg/day) in the treatment of acutely psychotic patients with schizophrenia.
Methods: Patients were randomly assigned to 6 weeks of double-blind treatment with lurasidone 160 mg/day (n=105) or QXR 600 mg/day (n=105). Primary efficacy measure was the change from baseline to week 6 in Positive and Negative Syndrome Scale (PANSS) total score and Clinical Global Impressions severity (CGI-S) score.
Article Synopsis
- The study investigated the similarities and differences between schizophrenia and autism by examining individuals with recent-onset psychosis and their autistic symptoms.
- Researchers analyzed 671 patients and found that those with more severe autistic symptoms had a higher likelihood of being diagnosed with schizophrenia and faced worse cognitive and functional outcomes.
- Longitudinal assessments indicated that the impacts of autistic symptoms on overall health and recovery were consistent over two years, highlighting their importance in predicting both symptom relief and functional improvement.
Article Synopsis
- * Researchers developed a method using mass spectrometry to analyze 453 peptides in nondepleted plasma from 132 individuals with various psychiatric disorders and healthy controls.
- * The findings indicated that specific protein markers could effectively differentiate between major psychiatric disorders and healthy controls, suggesting nondepleted plasma may improve psychiatric evaluations.
Article Synopsis
- The study challenges the current classification of major depressive disorder (MDD) and bipolar disorder (BD) due to a lack of strong biological evidence, suggesting a closer look at plasma proteins could offer insights.
- Researchers analyzed plasma samples from 299 patients with MDD or BD, identifying six protein modules through a weighted correlation network analysis.
- Findings linked specific protein modules with childhood trauma and overeating symptoms, highlighting these factors as important in understanding affective disorders, but no clear biological differentiation between MDD and BD was established.
Background: A post-marketing surveillance study was conducted to assess the real-world safety and effectiveness of vortioxetine for the treatment of major depressive disorder (MDD) in South Korea.
Methods: Adult patients aged 19-94 years receiving vortioxetine for MDD at 72 hospitals and clinics in South Korea between 19 August 2014 and 18 August 2020 were included. Patients were followed for up to 24±2 weeks, at up to three visits.
Data-driven approaches to subtype transdiagnostic samples are important for understanding heterogeneity within disorders and overlap between disorders. Thus, this study was conducted to determine whether plasma proteomics-based clustering could subtype patients with transdiagnostic psychotic-affective disorder diagnoses. The study population included 504 patients with schizophrenia, bipolar disorder, and major depressive disorder and 160 healthy controls, aged 19 to 65 years.
View Article and Find Full Text PDFArticle Synopsis
- The study focused on identifying key factors that influence recovery in patients with early stage schizophrenia spectrum disorders (SSD) over a follow-up period of up to 6.5 years.
- Researchers evaluated 375 patients using strict criteria for full recovery, including specific scores on the Positive and Negative Syndrome Scale (PANSS) and adequate functional recovery.
- The findings revealed that factors like negative symptoms, duration of untreated psychosis, and job status were significant predictors of recovery, emphasizing the importance of tailored treatment strategies based on individual clinical conditions.
Article Synopsis
- Corrected QT-interval (QTc) prolongation (QTP) is a serious but uncommon side effect of antipsychotic medications, particularly clozapine, which is used for treatment-resistant schizophrenia.
- A study of 133 patients on clozapine showed that a significant percentage experienced QTP, with higher doses of clozapine and other antipsychotics being linked to this condition.
- The research concluded that measuring clozapine blood concentration (therapeutic drug monitoring) can effectively predict the risk of QTP, particularly when levels exceed 600 mg/dL.
In the present study, various outcomes over 3-year period in patients with early stage psychosis including remission, recovery, relapse and medication adherence were investigated. Predictor for full recovery at year 3 was also examined. Three-year follow-up data in 534 patients with schizophrenia spectrum disorders (SSD) and psychotic disorder not otherwise specified (PNOS) were examined for overall outcome trajectories.
View Article and Find Full Text PDFBoron neutron capture therapy (BNCT) is a radiation therapy that selectively kills cancer cells and is being actively researched and developed around the world. In Korea, development of the proton linear accelerator-based BNCT system has completed development, and its anti-cancer effect in the U-87 MG subcutaneous xenograft model has been evaluated. To evaluate the efficacy of BNCT, we measured B-enriched boronophenylalanine (BPA) uptake in U-87 MG, FaDu, and SAS cells and evaluated cell viability by clonogenic assays.
View Article and Find Full Text PDFObjectives: Dopamine receptor D2 gene (DRD2) and glucocorticoid receptor gene (NR3C1) are implicated in the development of psychosis. We investigated methylation levels of DRD2 and NR3C1 in peripheral blood of patients with recent-onset (RO) psychosis using bisulfite pyrosequencing as well as its association with childhood trauma and rumination.
Methods: In all, 51 individuals with RO psychosis and 47 healthy controls were recruited.
Article Synopsis
- The study focuses on creating the Korea Polyenvironmental Risk Score (K-PERS) to understand risk factors for developing psychosis, specifically targeting the differentiation between patients with schizophrenia spectrum disorders (SSDs) and healthy individuals (HCs).
- Existing measurement tools were reviewed to construct K-PERS, which includes two versions: K-PERS-I (five factors) and K-PERS-II (six factors); both effectively distinguished between SSD and HC groups.
- Results indicated a significant correlation between K-PERS scores and negative symptoms of psychosis, highlighting the tool's potential for further research into clinical outcomes related to schizophrenia.
The classic subtype classification of schizophrenia has been removed, and DSM-5 now includes the Clinician-Rated Dimensions of Psychosis Symptom Severity (CRDPSS). In the present study, a factor analysis of the CRDPSS was performed, and we assessed whether patient classification using the derived factor structure helps predict the clinical course. The participants were 390 patients with recent-onset psychosis enrolled in the Korean Early Psychosis Cohort Study (KEPS).
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to explore the demographic, clinical features, cognitive functions, and 1-year outcomes of patients with psychotic disorder not otherwise specified (PNOS) compared to those with early-stage schizophrenia (SZ).
- Researchers assessed 54 PNOS patients and 321 SZ patients, with follow-ups revealing differences in symptom severity, treatment response, and compliance.
- Results showed that PNOS patients had better diagnostic stability, symptom severity, and treatment response but lower compliance, indicating that PNOS may be a distinct clinical condition requiring unique treatment strategies.
Childhood trauma (ChT) is a risk factor for psychosis. Negative lifestyle factors such as rumination, negative schemas, and poor diet and exercise are common in psychosis. The present study aimed to perform a network analysis of interactions between ChT and negative lifestyle in patients and controls.
View Article and Find Full Text PDFAim: In the present study, the prevalence and predictors of symptomatic and full remission were investigated in patients with first-episode psychosis (FEP) at the 12-month follow-up.
Methods: A total of 308 participants aged 18-45 years fulfilled the study inclusion criteria and 214 completed the 12-month follow-up.
Results: At the 12-month follow-up, 67.
Major depressive disorder (MDD) is the most common mood disorder, and causes various mental, physical and cognitive symptoms. Clinicians diagnose MDD using multiple interviews and overall impression during the interviews, which makes MDD diagnosis highly subjective. To overcome this, we investigated novel protein biomarker for MDD.
View Article and Find Full Text PDFBecause major depressive disorder (MDD) and bipolar disorder (BD) manifest with similar symptoms, misdiagnosis is a persistent issue, necessitating their differentiation through objective methods. This study was aimed to differentiate between these disorders using a targeted proteomic approach. Multiple reaction monitoring-mass spectrometry (MRM-MS) analysis was performed to quantify protein targets regarding the two disorders in plasma samples of 270 individuals (90 MDD, 90 BD, and 90 healthy controls (HCs)).
View Article and Find Full Text PDFMajor depressive disorder (MDD) is a common disorder involving depressive mood and decreased motivation. Due to its high heterogeneity, novel biomarkers are required to diagnose MDD. In this study, a proteomic method was used to identify a new MDD biomarker.
View Article and Find Full Text PDFBackground: Network approach has been applied to a wide variety of psychiatric disorders. The aim of the present study was to identify network structures of remitters and non-remitters in patients with first-episode psychosis (FEP) at baseline and the 6-month follow-up.
Methods: Participants ( = 252) from the Korean Early Psychosis Study (KEPS) were enrolled.
Introduction: A psychotic relapse of schizophrenia is commonly preceded by nonpsychotic behavioral symptoms and signs, and detection of these early signs may enable prevention of relapse of schizophrenia. This study aimed to test the predictive validity of a Korean version of Early Signs Scale (K-ESS) for psychotic relapse for detecting the early signs.
Materials And Methods: In this multicenter noninterventional 52-week prospective study, outpatients diagnosed as having schizophrenia within 5 years were recruited.